Next 10 |
home / stock / opt / opt articles
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-st...
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (M...
MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopha...
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage bioph...
MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage bioph...
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage ...
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical co...
MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT, "Opthea")), a clinical-stage biopharmaceutical com...
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track r...
News, Short Squeeze, Breakout and More Instantly...
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, incl...
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows successful Institutional Entitlement Offer and institutional Placement raising approxima...
Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal Ophthalmology and Therapy MELBOURNE, Australia and PRINCETON, N.J....